Revive's corporate update centers on psilocybin research on a new delivery system and addiction treatment.
Exploring the companies and themes that make up this emerging and exciting new sector
Numinus Announces Listing of Warrants
Numinus warrants have an exercise price of CAD$0.35 and are valid until September 10, 2022.
Mind Cure Targets Multi-Billion Dollar Sweet-Spot in Life Sciences
The road to psychedelic drug success leads through functional mushrooms.
Compass’s Upsized IPO Financing Sends ‘Buy’ Signal For Sector
Compass has boosted its IPO financing by roughly 20% AND increased the unit price -- signalling strong interest in the psychedelic space.
Mind Cure Announces Closing of Oversubscribed Upsized Initial Public Offering
Newest IPO hits September 21- MCUR
Functional Mushrooms: The Psychedelics Stepping Stone
Functional mushrooms are a large-and-growing health supplements market with synergies to psychedelics operations.
Champignon Provides Update on Disclosure Review
Champignon Brands continues to work with the BC Secutiries Commission to complete its disclosure review.
Mydecine Innovations Group, Inc. to Create Special Committee for the Spin Out of US Related Assets
Mydecine is planning to spin out its U.S. legacy cannabis assets.
Compass Pathways Raising Up To $107.2 million For IPO, Valuation $500+ Million
Compass Pathways has set the terms for its IPO, targeting a valuation at or about $544.1 million.
Is Psilocybin More Revolutionary Than Spravato for Depression?
Spravato has not been the "game-changer" for treating depression that it was touted as being. The market remains wide open for psilocybin (and other psychedelics).
Psychedelics Company Havn Life Announces Commencement of Public Trading on the CSE
Havn Life Sciences commences trading on the CSE under the ticker symbol "HAVN".
ATAI Positioned As Kingmaker In Psychedelics Space
ATAI Life Sciences is looking more and more like the driving force in the psychedelic drug industry.